Refarmed Chemicals presents Ciprofibrate, a crucial pharmaceutical material developed for clinical efficacy in managing lipid disorders. Developed with the utmost precision, Ciprofibrate is a fibrate-class drug specially formulated as a therapeutic agent to regulate high levels of cholesterol and triglycerides, factors leading to cardiovascular diseases. Our product is synthesized with rigorous compliance to quality standards, evidenced by its Good Manufacturing Practice (GMP) certification. The drug appears as a white or slightly yellow-white crystalline powder, indicative of its purity. Highly soluble in anhydrous ethanol and toluene yet practically insoluble in water, Ciprofibrate facilitates flexibility in pharmaceutical formulation, allowing for both tablet and capsule dosage forms in strengths of 100mg and 200mg. Targeting primary hypercholesterolemia (type IIa or IIb), mixed dyslipidemia, and as preventive treatment against cardiovascular events in high cholesterol patients, Ciprofibrate's composition facilitates the acceleration of cholesterol and triglyceride breakdown and removal from the body. Recommended for bi-daily intake alongside meals, the treatment's efficacy is augmented by adherence to healthy lifestyle choices, including a balanced diet and regular exercise. Safety parameters dictate careful administration especially to those with a history of gallbladder disease, and periodic liver function evaluations are advised. Contraindications include severe renal or hepatic conditions, pregnancy, breastfeeding, or known hypersensitivity to fibrates. Consultation with healthcare professionals is critical when concomitant medications are involved, particularly statins, anticoagulants, and antibiotics. Storage requirements for Ciprofibrate are straightforward — room temperature conditions away from light and moisture ensure stability. As a product from the storied catalogue of Refarmed Chemicals, now part of the DKSH Group, Ciprofibrate is accompanied by dependable documentation for Detailed and Master Files, affirming its reputable standard in pharmaceutical resources.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals proudly presents Carbocisteine Lysine salt monohydrate, a meticulously crafted mucolytic agent essential for healthcare professionals treating patients with respiratory tract disorders. This fine, white to slightly yellow powder exhibits high-quality performance, designed to alleviate conditions like chronic bronchitis, COPD, pneumonia, and cystic fibrosis through its ability to degrade thick, viscous mucus, facilitating easier expectoration and promoting respiratory comfort. Formulated for oral administration as a soluble powder, Carbocisteine Lysine salt monohydrate ensures convenient dosing flexibility. Each sachet contains a precisely calibrated amount of the active ingredient, offering consistent therapeutic efficacy. The typical adult dosage is 750 mg thrice daily, with adjustments made to accommodate individual patient needs by healthcare providers. Quality assurance is at the heart of our corporate ethos. This product conforms to stringent standards, with every batch undergoing rigorous testing to confirm solubility, identification, pH balance, and purity. Our assay guarantees a potency range of 98.0% - 101.0%, ensuring that each dose delivers the expected therapeutic effect. Furthermore, the product's compliance with heavy metal regulations and the meticulous control of residual solvents like ethanol underline our commitment to safety. Moreover, Carbocisteine Lysine salt monohydrate accommodates a broad spectrum of patients, with sensible precautions established for those with a history of gastrointestinal issues or hypersensitivity to its constituents. This product should be used under medical supervision, especially for those with liver or kidney impairments, or during pregnancy and lactation. It is contraindicated in individuals with active peptic ulcers. Storage is straightforward—simply keep the product in a cool, dry environment below 25°C, away from light and moisture, to maintain its integrity. Available in various package sizes, this pharmaceutical offers adaptability for different clinical settings and patient requirements. Choose Carbocisteine Lysine salt monohydrate for dependable respiratory support, backed by the trusted name of Refarmed Chemicals, a company aspiring towards delivering growth in Asia and beyond.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Refarmed Chemicals presents Alacepril, a premium-grade antihypertensive medication catering to the pharmaceutical industry's mandate for efficacy and safety. This ACE (Angiotensin-converting enzyme) inhibitor is an integral pharmaceutical compound used in the treatment of hypertension and to mitigate the risk of myocardial infarction in patients with left ventricular dysfunction. By inhibiting ACE, Alacepril decreases the production of angiotensin II, resulting in vasodilation, reduced vascular resistance, and consequently, lower blood pressure. Constructed as a white crystalline powder, Alacepril is noted for its commendable solubility in methanol and ethanol (95%), with moderate solubility in water, facilitating its versatile use in different medicinal formulations. With quality as its cornerstone, Alacepril assures a high purity level, with an assay (by titration) confirming a 98.0% to 101.0% concentration for optimal therapeutic benefit. Each impurity is rigorously controlled to ≤ 0.2% and total impurities to ≤ 0.5%, ensuring compliance with robust pharmaceutical standards. Alacepril is packaged with comprehensive documentation, including DMF and JDMF certifications, and is produced under EU GMP guidelines, reflecting an unwavering commitment to regulatory conformance and product integrity. Precautionary measures are accounted for, with guidelines established for patients with hepatic or renal impairment, and contraindications identified for populations at risk, including during pregnancy and when potential for specific drug interactions exists. With a rapid absorption and an onset of action within 1-2 hours, Alacepril maintains its therapeutic efficacy for approximately 24 hours, making it a convenient once-daily treatment. Renal excretion serves as its primary elimination pathway, underscoring the need for tailored dose adjustments in patients with renal impairment. Trust Alacepril from Refarmed Chemicals for effective blood pressure management, anchored by our dedication to safety, efficacy, and quality control. Experience the synergy of cutting-edge pharmaceutical science and comprehensive patient care with Alacepril—a flagship example of our mission to support health and well-being.

Products still subject to third-party patent protection might be available solely for R&D purposes.

Deferasirox, marketed under the brand Refarmed Chemicals, is a cornerstone in the treatment of chronic iron overload due to blood transfusions in conditions such as thalassemia and sickle cell disease. This condition, if not properly managed, can have severe consequences for organ function. Deferasirox is available in oral tablet form, with strengths of 250 mg, 500 mg, and 1000 mg, allowing for flexibility and precision in dosing to meet individual patient needs. Crafted as an iron chelator, Deferasirox plays a crucial role in binding excess iron within the body and facilitating its excretion through urine. This targeted mechanism asserts its importance in maintaining a healthy balance of iron and preventing the potential toxicity associated with overload. Patients are advised to take Deferasirox with or without food, adhering to a dosing schedule that is tailored to their specific iron levels and bodily response, underscoring the need for a personalized approach to treatment. Regarding its physical properties, Deferasirox appears as a white to pale yellowish crystalline powder, primarily soluble in DMF (Dimethylformamide) and slightly soluble in methanol. These characteristics are essential for ensuring its effectiveness and stability as a pharmaceutical agent. It is imperative that patients undergo regular blood tests and health monitoring for optimum results and to prevent adverse effects such as gastrointestinal distress, skin reactions, and potential liver or renal impairment. Additionally, care must be taken in cases of known hypersensitivity to Deferasirox or pre-existing severe renal or liver conditions. Our documentation and certifications like Good Manufacturing Practice (GMP) and the Drug Master File (DMF) guarantee the highest levels of quality and compliance with industry standards. It is our priority to ensure that this crucial pharmaceutical material is of the utmost purity and efficacy, as reflected in our stringent quality control parameters including the presence of residual solvents and related substances, all documented for your assurance. Please note that while Deferasirox is a vital medication for many patients, it requires diligent medical supervision. Always consult healthcare professionals for specific medical advice and treatment instructions tailored to individual health profiles.

Products still subject to third-party patent protection might be available solely for R&D purposes.